Fibroblast Growth Factor Receptor 3 clinical trials
15 active trials name this biomarker in their eligibility criteria. Describe your situation to see which ones you may be eligible for.
- Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
- A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
- Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
- Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
- Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
- A Study of TYRA-300 in Children With Achondroplasia: BEACH301
- FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
- Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)
- IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies
- A Phase 1 Study of BHV-1530 in Advanced Solid Tumors
- Prospective Clinical Assessment Study in Children With Hypochondroplasia
- Extension Study of Infigratinib in Children With Achondroplasia (ACH)
- Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia
- An Interventional Study of Infigratinib in Children With Hypochondroplasia
Guides for people searching for a trial
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that name “Fibroblast Growth Factor Receptor 3” in their eligibility criteria, at any level. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.